This article is more than 5 years old. Information may no longer be current.
No difference found in corneal thickness after bevacizumab injection
Am J Ophthalmol. 2008;146(5):688-691.
Intravitreal injection of bevacizumab appears to have no toxic effects on corneal endothelial cells in patients receiving either a single dose or three doses.
In 50 eyes of 50 patients receiving a 2.5-mg injection of Avastin (bevacizumab, Genentech), there was no difference in endothelial cell density 3 months and 6 months after injection compared with baseline measurements in either the treated eye or the untreated fellow eye.
A subset of 12 patients with age-related macular degeneration in the prospective study received three injections. “There was no significant difference in the treated eyes before injection and 6 months after injection,” the study said.
Differences in mean corneal thickness were also not significant between treated and untreated eyes on day 1 or day 7 after injection. In treated eyes, there was no difference in mean corneal thickness compared with baseline on day 1 or day 7 after injection.